, Volume 92, Issue 6, pp 855-857
Date: 25 Nov 2012

Hodgkin’s lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

A 54-year-old man, with good past health, was diagnosed to have International Stage III, IgG myeloma in Dec 2006 with IgG M-protein measuring 116 g/L, serum albumin 22 g/L (normal, 40–50 g/L), β2-microglobulin of 9.25 mol/L, and 56 % plasma cell infiltration of the bone marrow at diagnosis. He achieved a partial remission with a 83 % reduction of M-protein to 15 g/L after the induction with the staged approach [1, 2], which comprised three cycles of vincristine, adriamycin, and dexamethasone (VAD), followed by four cycles of salvage bortezomib, thalidomide, and dexamethasone in patients failing a ≥75 % reduction in M-protein level after VAD. He achieved very good partial response (i.e., >90 % reduction of M-protein) and immunofixation-negative complete remission (CR) at 3 and 6 months after autologous stem cell transplantation (ASCT) in July 2007. He was entirely asymptomatic until May 2012 when he complained of a painless left cervical lymph node. Excisional lymph node bio